The company's principal activity is to discover and develop pharmaceutical products for the treatment of diabetes and cardiovascular aging. These products are developed as a result of a research on a pathological process, the advanced glycosylation end-product pathway. This process causes or contributes to many medical disorders, including cardiovascular, kidney and eye diseases. The product alt-711 inhibits, measures and reverses damage to cells, tissues and organs caused by it. Another product, alt-744 is being clinically evaluated in skin aging for cosmetic applications. Pimagedine is a lead compound employed by the company. It has been licensed to yamanouchi pharmaceutical co, ltd for commercial distribution in Japan, South Korea, Taiwan and the People's Republic of China. The company has also entered into an exclusive licensing arrangement with roche diagnostics gmbh for development of drug therapies and diagnostics utilizing its scientific platforms.
Executive Information
Name
Title
Email
Carl Mendel
VP - Clinical Development, Chief Medical Officer
N/A
Malcolm MacNab
VP - Clinical Development
N/A
Jacob Victor
Executive Dir. - Product Development, Clinical Diagnostics
